ArticleAddiction (Abingdon, England)2025
Exploratory analysis of United States-based cannabis product health benefit claims on online marketplaces.
Article in Addiction (Abingdon, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsCannabis-derived products (CDPs), including cannabidiol (CBD) and tetrahydrocannabinol (THC) products, are widely diverse and readily available through physical and online retail channels in the United States (US) marketplace and may also include claims of treating or providing benefit for health issues. This study aimed to systematically classify the various types of health benefit claim(s) present on CDP listings based on publicly available online marketplace data.
designExploratory analysis to identify health benefit claims. SETTING AND CASES: A total of 624 805 unique CDPs sold in the US on Leafly and Weedmaps, cannabis online marketplace service platforms. MEASUREMENTS: This exploratory study was conducted in four phases: (1) data mining of cannabis e-commerce websites Weedmaps and Leafly for product listings in the US; (2) data filtering, text matching and content coding to identify types of advertised health benefit(s) made; (3) analysis on consumer-generated product reviews for sentiment toward advertised health benefit(s); and (4) ANOVA was used to test differences in mean number of health benefit claims based on product characteristic of route-of-administration (RoA).
findingsA total of 624 805 unique US CDP sales listings from Leafly (n = 50 951) and Weedmaps (n = 573 854) were analyzed. CDP listings with a specific health benefit claim(s) were detected in 998 (1.9%) Leafly and 25 671 (4.47%) Weedmaps CDP listings. The top 5 advertised health benefits were treatment of mood disorders, general discomfort, general wellness, sleep disorders and chronic conditions. Among consumer reviews, 295 (4.6% of consumer reviews from products that advertised health benefit(s)) expressed sentiment toward CDP addressing their health issue with 82.4% being positive, 14.6% negative and 3.1% neutral. We also observed statistically significant differences between RoA and frequency of health benefit claims among those with at least one health benefit claim, with multisystem products (>1RoA) generally having a higher number of average health benefit claims compared with other RoAs.
conclusionsOver 26 000 cannabis-derived products listed on two popular US cannabis online marketplaces have at least one health benefit claim.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.